MDS Inc. Announces Normal Course Issuer Bid

    TORONTO, June 30 /CNW/ - MDS Inc. (TSX: MDS, NYSE:   MDZ), a leading
provider of enabling products and services to the global life sciences
markets, announced today that the Toronto Stock Exchange (TSX) accepted the
Company's Notice of Intention to make a normal course issuer bid for a
one-year period.
    The Notice provides that during the twelve months commencing July 3, 2008
and ending July 2, 2009, if deemed appropriate by the Chief Executive Officer
and Chief Financial Officer of the Company, MDS may purchase up to 4,136,766
MDS Common shares on the Toronto Stock Exchange and the New York Stock
Exchange. This represents approximately 5% of the public float. At June 20,
2008, there were 122,028,330 Common shares issued and outstanding and
82,735,313 Common shares in the public float. All shares purchased by MDS
under this normal course issuer bid will be promptly cancelled. Daily
purchases will be limited to 130,250 Common shares, other than block purchase
    Under the Company's previous normal course issuer bid, which began on
July 3, 2007 and ends on July 2, 2008, MDS has purchased and cancelled
1,235,300 Common shares to date.
    Since all purchases of MDS Common shares under the normal course issuer
bid would be made on the open market, the Company is not in a position to know
the identity of the parties from whom it may purchase Common shares. The
Company believes that the purchase of outstanding Common shares at certain
times during the normal course issuer bid period may enhance value for
shareholders and is an appropriate use of funds.

    This document contains forward-looking statements. Some forward-looking
statements may be identified by words like "expects", "anticipates", "plans",
"intends", "indicates" or similar expressions. The statements are not a
guarantee of future performance and are inherently subject to risks and
uncertainties. The Company's actual results could differ materially from those
currently anticipated due to a number of factors, including, but not limited
to, successful integration of structural changes, including restructuring
plans, acquisitions, technical or manufacturing or distribution issues, the
competitive environment for the Company's products, the degree of market
penetration of the Company's products, and other factors set forth in reports
and other documents filed by the Company with Canadian and US securities
regulatory authorities from time to time.

    About MDS

    MDS Inc. (TSX: MDS; NYSE:   MDZ) is a global life sciences company that
provides market-leading products and services for the development of drugs and
diagnosis and treatment of disease. We are a leading global provider of
pharmaceutical contract research, medical isotopes for molecular imaging,
radiotherapeutics, and analytical instruments. MDS Inc. has more than 5,500
highly skilled people in 29 countries. Find out more at or by
calling 1-888-MDS-7222, 24 hours a day.

For further information:

For further information: Investors: Kim Lee, MDS Inc., (416) 675-6777 x
34721,; Media: Janet Ko, MDS Inc., (416) 675-6777 x 34167,

Organization Profile

Nordion Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890